Oppenheimer lowered the firm’s price target on Sagimet Biosciences (SGMT) to $25 from $30 and keeps an Outperform rating on the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMT:
- Sagimet Biosciences Reports Q1 2025 Financial Results
- Sagimet Biosciences Reports Q1 Financial Results and Updates
- Sagimet Biosciences reports Q1 EPS (56c), consensus (69c)
- Sagimet Biosciences announces presentations at EASL Congress 2025
- Sagimet Biosciences: Promising Future with Phase 3 MASH Trials and Strong Financial Position
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue